VISUDYNE Drug Patent Profile
✉ Email this page to a colleague
When do Visudyne patents expire, and what generic alternatives are available?
Visudyne is a drug marketed by Valeant Luxembourg and is included in one NDA.
The generic ingredient in VISUDYNE is verteporfin. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the verteporfin profile page.
Summary for VISUDYNE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 23 |
Clinical Trials: | 57 |
Patent Applications: | 6,957 |
Drug Prices: | Drug price information for VISUDYNE |
What excipients (inactive ingredients) are in VISUDYNE? | VISUDYNE excipients list |
DailyMed Link: | VISUDYNE at DailyMed |
Recent Clinical Trials for VISUDYNE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Wake Forest University Health Sciences | Phase 4 |
Singapore National Eye Centre | N/A |
Tan Tock Seng Hospital | N/A |
Pharmacology for VISUDYNE
Drug Class | Photoenhancer |
Mechanism of Action | Photoabsorption |
Physiological Effect | Photosensitizing Activity |
Anatomical Therapeutic Chemical (ATC) Classes for VISUDYNE
US Patents and Regulatory Information for VISUDYNE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Valeant Luxembourg | VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119-001 | Apr 12, 2000 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VISUDYNE
EU/EMA Drug Approvals for VISUDYNE
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
CHEPLAPHARM Arzneimittel GmbH | Visudyne | verteporfin | EMEA/H/C/000305 Visudyne is indicated for the treatment of:adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or;adults with subfoveal choroidal neovascularisation secondary to pathological myopia. |
Authorised | no | no | no | 2000-07-27 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for VISUDYNE
See the table below for patents covering VISUDYNE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Africa | 9701820 | ⤷ Try a Trial | |
Japan | 2835294 | ⤷ Try a Trial | |
Germany | 69733943 | ⤷ Try a Trial | |
Poland | 188888 | ⤷ Try a Trial | |
Germany | 69334009 | ⤷ Try a Trial | |
Portugal | 843547 | ⤷ Try a Trial | |
Hong Kong | 1018203 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VISUDYNE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0352076 | 2001C/010 | Belgium | ⤷ Try a Trial | PRODUCT NAME: VERTEPORFIN; NAT. REGISTRATION NO./DATE: EU/1/00/140/001 20000727; FIRST REGISTRATION: CH 55269 19991215 |
0352076 | C300037 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: VERTEPORFINE, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/00/140/001 20000727 |
0352076 | 1/2001 | Austria | ⤷ Try a Trial | PRODUCT NAME: VERTEPORFIN; REGISTRATION NO/DATE: EU/1/00/140/001 20000727 |
0352076 | SPC/GB01/005 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: VERTEPORFIN OPTIONALLY IN THE FORM OF A SALT THEREOF; REGISTERED: UK EU/1/00/140/001 20000727 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |